19.65 -0.06 (-0.30%)
After hours: 7:57PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||19.20 - 20.39|
|52 Week Range||8.31 - 22.81|
|PE Ratio (TTM)||5.03|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Disney (DIS) is spending $52 billion for most of 21st Century Fox’s (FOXA) film and TV assets. Disney shares are up over 2% on the deal news. Disney will also take on about $13 billion in debt.
LAVAL, Quebec, Dec. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on December 18, 2017 (the "Early Settlement Date"). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.
Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, recovering from a downgrade from JPMorgan yesterday, but investors shouldn't get too comfortable, warns Mizuho Securities. Analyst Irina Koffler reiterated an Underperform rating on the stock today, although she did raise he price target from $7 to $10. Koffler writes that while 2018 EBITDA guidance may not be "that disappointing," but she's not willing to abandon her bear thesis ahead of it.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) almost shook off a bear from its tail amid some impressive turnaround efforts to "deftly" refinance debt. Mizuho analyst Irina Rivkind Koffler all the same does look for a "negative" reaction to the comeback stock of the Street in terms of the 2018 guide and underscores fears of a dilutive financing event, especially considering the latest rally.
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
U.S. equities fell on Thursday amid doubts over the fate of the GOP’s tax cut plans. The doubt hit investors after a number of Republican senators expressed reservations about the amount of the child tax credit. In the end, the Dow Jones Industrial Average lost 0.3%, the S&P 500 lost 0.4%, the Nasdaq Composite lost 0.3% and the Russell 2000 lost 1.2%.
Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.
Have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares just gotten too expensive? Shares are tumbling 10% after a cautious analyst decided it is no longer wise to play it safe, deciding to step away from the sidelines on VRX. The reason? The struggling biotech giant's estimates for the next two years seem too ambitious. Moreover, now after shares have rallied close to 100% from the stock price before the third quarter print, Valeant's valuation simply does not make a "compelling" argument to invest.
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.